Navigation Links
Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
Date:9/7/2009

era MO, Jullien D, Lavergne O, Frongia C, Bigg D, Kasprzyk PG, Prevost GP, Ducommun B.

    For further information:

    Ipsen

    Media
    Didier Veron
    Director, Public Affairs and Corporate Communications
    Tel.: +33(0)1-58-33-51-16
    Fax: +33(0)1-58-33-50-58
    E-mail: didier.veron@ipsen.com

    Financial Community
    David Schilansky
    Investor Relations and Financial Officer
    Tel.: +33(0)1-58-33-51-30
    Fax: +33(0)1-58-33-50-63
    E-mail: david.schilansky@ipsen.com

    Pierre Kemula
    Investor Relations Manager
    Tel.: +33(0)1-58-33-60-08
    Fax: +33(0)1-58-33-50-63
    E-mail: pierre.kemula@ipsen.com

    Debiopharm S.A.
    Maurice Wagner
    Director Corporate Affairs & Communication
    Tel.: +41(0)21-321-01-11
    Fax: +41(0)21-321-01-69
    mwagner@debiopharm.com



'/>"/>
SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
2. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
3. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
6. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
7. Japanese Cancer Association and Debiopharm Honour Japanese Research
8. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
9. Debiopharm and EPFL Establish an Oncology Chair
10. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
11. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... WASHINGTON, New York , September 23, 2014 ... ), a leading provider of  Closed System Transfer   ... a new exclusive partnership with Taiwanese distributor MedFront Medical Technology ... regulatory bodies in Taiwan , ... for approval as the company continues to expand ...
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 Marktech ... of deep ultra violet emitters in the 280 nm ... standard UV emitters which range from 280nm to 405nm. ... and water sanitation as well as curing. Mark Campito, ... line of special interest to manufacturers is that we ...
(Date:9/23/2014)... 2014 Healthcare professionals, patients ... convene at the Society for Integrative Oncology ... October 26-28 in Houston, Texas to discuss ... in individualized integrative cancer care. This multi-disciplinary ... nutritionists, naturopaths, acupuncturists, and other complementary care ...
(Date:9/23/2014)... September 23, 2014 New ... Imperial Innovations, Cambridge Innovation Capital and Johnson & ... cancer genomics company focused on harnessing the potential ... cancer testing and treatment, today announced it has ... Imperial Innovations and including Cambridge Innovation Capital and ...
Breaking Biology Technology:Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2Marktech Introduces its New Line of Deep UV Emitters 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4
... definition has potential to revolutionize,endoscopic surgery, LAS ... glimpse into the,future of women,s healthcare with the ... first time using "4K" technology, at the 37th,Global ... AAGL. AAGL,is the international professional society for specialists ...
... Nutrition 21, Inc.,(Nasdaq: NXXI ) today ... and general manager of the Company,s Direct Response ... than 22 years of,experience in sales, marketing, management ... McWilliams, responsibilities include new,business development, sales strategy, vendor ...
... Va., Oct. 30 Insmed Inc. (Nasdaq:,INSM), a developer of follow-on biologics ... 30,2008., Recent Company Highlights, -- Follow-on Biologics Program ... Kingdom,s Medicines and ... study for the Company,s second ...
Cached Biology Technology:Women's Surgery Recorded for the First Time on '4K' Digital Cinema is Presented at the AAGL Congress 2Nutrition 21 Appoints Pam McWilliams, Vice President - General Manager of Direct Response 2Nutrition 21 Appoints Pam McWilliams, Vice President - General Manager of Direct Response 3Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 2Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 3Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 4Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 5Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 6Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 7Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 8Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 9Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 10
(Date:9/22/2014)... Antarctic fishes that manufacture their own "antifreeze" proteins ... suffer an unfortunate side effect, researchers report: The ... resist melting even when temperatures warm. , ... of the National Academy of Sciences . , ... consequence of the evolution of antifreeze proteins in ...
(Date:9/22/2014)... (September 22, 2014)The Brain & Behavior Research ... of NARSAD Young Investigator Grants valued at ... the world,s most promising young scientists. Recipients ... neurobiological research will seek to identify causes, ... psychiatric disorders that affect one in four ...
(Date:9/22/2014)... Mobile robots could be much more useful in homes, ... robots usually see the world with cameras and lasers, ... objects that are hidden in clutter. A complementary way ... the use of small ultra-high frequency radio-frequency identification (UHF ... objects, allowing an RFID-equipped robot to search a room ...
Breaking Biology News(10 mins):Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3Brain & Behavior Research Foundation awards 200 NARSAD Young Investigator grants 2New RFID technology helps robots find household objects 2New RFID technology helps robots find household objects 3
... of researchers from The University of Texas at Dallas have ... the technologies of the next generation. One UT Dallas ... with the goal of creating faster electronics that use dramatically ... computer architecture that allows the many types of computers used ...
... on January 22, 2013, a team of paleontologists including Dr. ... Angeles County,s (NHM) Dinosaur Institute, has discovered a way to ... Confuciusornis sanctus , a 125-million-year-old Mesozoic bird, had remarkable ... ornamental tail feathers, others had none features that have ...
... Biologist Erica Larschan, Ph.D., was named by The ... innovative findings on chromosomal activity in fruit flies. 2011 Pew Biomedical ... in identifying a protein that allows a male fruit fly to ... proven similar in human males, could point the way to treatments ...
Cached Biology News:UT Dallas researchers awarded $4.3 million to create next-generation technologies 2UT Dallas researchers awarded $4.3 million to create next-generation technologies 3UT Dallas researchers awarded $4.3 million to create next-generation technologies 4Sex of early birds suggests dinosaur reproductive style 2